Zydus Lifesciences’ wholly-owned subsidiary -- Sentynl Therapeutics, Inc. (Sentynl) has received marketing authorisation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for NULIBRY (fosdenopterin) for Injection as the first therapy for the treatment of patients in Great Britain (GB) with Molybdenum Cofactor Deficiency (MoCD) Type A. This is an ultra-rare, life-threatening genetic disorder that often progresses rapidly in infants.
It is known to impact fewer than 150 patients globally with a median survival age of four years. NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy that was approved by the U.S. Food and Drug Administration (USFDA) in 2021 to reduce the risk of mortality in patients with MoCD Type A. Following this decision by the UK MHRA, NULIBRY is the first and only approved therapy in GB for MoCD Type A.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: